Cognyte Software (NASDAQ:CGNT) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Cognyte Software (NASDAQ:CGNTFree Report) in a research note published on Friday morning, Benzinga reports.

A number of other research analysts also recently issued reports on the company. StockNews.com upgraded Cognyte Software from a buy rating to a strong-buy rating in a research note on Wednesday, April 10th. Wedbush raised their price objective on shares of Cognyte Software from $5.00 to $8.00 and gave the stock a neutral rating in a report on Thursday, April 11th. Finally, Evercore ISI lifted their price objective on shares of Cognyte Software from $5.00 to $7.50 and gave the stock an in-line rating in a research report on Wednesday, April 10th.

Get Our Latest Stock Report on CGNT

Cognyte Software Price Performance

Shares of CGNT stock opened at $7.68 on Friday. The firm has a 50-day moving average of $7.47 and a 200-day moving average of $6.63. Cognyte Software has a one year low of $4.00 and a one year high of $8.53. The company has a market cap of $545.43 million, a P/E ratio of -33.39 and a beta of 1.72.

Cognyte Software (NASDAQ:CGNTGet Free Report) last posted its quarterly earnings data on Tuesday, April 9th. The medical device company reported ($0.28) EPS for the quarter. Cognyte Software had a negative net margin of 4.97% and a negative return on equity of 12.06%. The firm had revenue of $83.69 million during the quarter. As a group, research analysts expect that Cognyte Software will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cognyte Software

Several institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC bought a new position in shares of Cognyte Software in the fourth quarter worth $37,000. Covestor Ltd purchased a new stake in Cognyte Software during the 1st quarter worth about $73,000. Quantbot Technologies LP bought a new position in Cognyte Software in the 3rd quarter worth about $57,000. Russell Investments Group Ltd. grew its holdings in Cognyte Software by 8,624.3% during the 4th quarter. Russell Investments Group Ltd. now owns 20,066 shares of the medical device company’s stock valued at $129,000 after buying an additional 19,836 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Cognyte Software by 56.1% during the fourth quarter. Mackenzie Financial Corp now owns 21,986 shares of the medical device company’s stock valued at $141,000 after buying an additional 7,899 shares during the period. 72.92% of the stock is owned by hedge funds and other institutional investors.

About Cognyte Software

(Get Free Report)

Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company offers network intelligence analytics, threat intelligence analytics, decision intelligence analytics, and operational intelligence analytics solutions.

See Also

Receive News & Ratings for Cognyte Software Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognyte Software and related companies with MarketBeat.com's FREE daily email newsletter.